Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observations in the hamster skin fold.
The effect of a clinically used purified micronized flavonoid fraction (90% diosmin and 10% hesperidin) on leukocyte-endothelial cell interaction during ischemia-reperfusion injury was studied in the microcirculation of unanesthetized hamsters fitted with a skin fold window chamber. The drug was given orally in suspension with arabic gum (30 mg/kg) 8 h prior to induction of 4-hour tourniquet ischemia in the chamber window. Leukocyte-endothelial cell interaction was observed using fluorescence intravital microscopy in postcapillary venules (15-70 microns in diameter) at control and during reperfusion at 30 min and 2 and 24 h. Leukocytes were classified according to their flow pattern as (1) 'passers', including 'free flowing' leukocytes and those which were 'flowing with endothelial contact', and (2) 'immobilized' leukocytes. Untreated animals exhibited a significant increase of 'immobilized' leukocytes and of those 'flowing with endothelial contact' during reperfusion. Flavonoid-treated animals displayed a statistically significant lower number of 'immobilized' leukocytes at all time points during reperfusion. There was no change in the number of leukocytes 'flowing with endothelial contact' relative to the untreated animals. Since firm leukocyte attachment to the endothelial wall and subsequent emigration of leukocytes into the interstitium is a mechanism for tissue damage during inflammation, attenuation of this phenomenon during conditions of ischemia-reperfusion can in part explain previous observations that this purified micronized flavonoid fraction decreases edema formation.
Friesenecker
B
B
Department of AMES-Bioengineering, University of California, San Diego, La Jolla 92093-0412.
Tsai
A G
AG
Allegra
C
C
Intaglietta
M
M
D000284:Administration, Oral; D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D005591:Chemical Fractionation; D006224:Cricetinae; D004304:Dosage Forms; D005419:Flavonoids / Q000302:isolation & purification / Q000494:pharmacology*; D007962:Leukocytes / Q000187:drug effects* / Q000473:pathology; D008647:Mesocricetus; D015427:Reperfusion Injury / Q000188:drug therapy / Q000473:pathology*; D012867:Skin / Q000187:drug effects / Q000473:pathology; D014741:Video Recording
D004304:Dosage Forms; D005419:Flavonoids